In May 2018, MAPS raised nearly $583,000 in new donations and pledges from 385 supporters.
Last month, Clay and Rebecca Rockefeller, the son and daughter of Richard Rockefeller, raised the remaining $500,000 needed for MAPS’ Phase 3 MDMA/PTSD studies in the U.S. to support FDA approval. Clay and Rebecca raised the funds within the Rockefeller family from themselves and their cousins in honor of their father’s philanthropic efforts and dedication to finding better treatments for PTSD in the last years of his life. With these gifts, MAPS has now raised the $26.7 million needed for its upcoming Phase 3 clinical trials for FDA approval.
MAPS is currently seeking $8 million for European Medicines Agency (EMA) trials to supplement the data gathered for the FDA, with $420,000 already raised and roughly $7.6 million still to go. MAPS will have a clearer estimate of costs for Phase 3 EMA trials after it completes its negotiations with EMA around the end of the Summer or Fall 2018. Supporters of MAPS’ European research have a special opportunity to have their gifts matched since MAPS has received a $500,000 matching grant for EMA with $210,000 already raised (and $210,000 matched) and $290,000 still to be matched.
We extend a special thanks to those who so generously supported MAPS last month:
- Adam Wiggins ($50,000)
- Shane Leather ($2,000)
- Michael Hamann ($1,000)
Phase 3 MDMA/PTSD:
- Clay & Rebecca Rockefeller & Cousins ($500,000)
- Patricia & Richard Simon ($10,000)
- Daniel Uvanovic ($1,000)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major non-family foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate